Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Resonance Specialties's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Specialties ROE % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Resonance Specialties's ROE % distribution charts can be found below:
* The bar in red indicates where Resonance Specialties's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Resonance Specialties (BOM:524218) has a ROE % of 25.10% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Resonance Specialties and its competitors. This is 112% above median its historical median of 11.85. According to the industry distribution chart, Resonance Specialties ranks #215 out of 1583 companies in the Chemicals industry, placing it in the top 13.6%.
Is Resonance Specialties' ROE % too high?
Resonance Specialties' current ROE % of 25.10% is 112% above median its 10-year median of 11.85. The Chemicals industry median ROE % is 5.26. Resonance Specialties' value of 25.10% is 377.2% above this industry median. Based on the distribution chart, Resonance Specialties ranks #215 out of 1583 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Resonance Specialties has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Resonance Specialties' ROE % compare to DOW?
According to the Chemicals industry distribution chart, Resonance Specialties ranks #215 out of 1583 companies for ROE %. This places Resonance Specialties in the top 14% of its industry — outperforming the majority of peers. The industry median ROE % is 5.26. Resonance Specialties' value of 25.10% is 377.2% above this benchmark. While the company's 10-year median is 11.85 vs. the industry median of 5.26, Resonance Specialties has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Chemicals company?
The median ROE % among Chemicals companies is 5.26, based on 1,583 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Specialties's current ROE % of 25.10% is 377.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Resonance Specialties and its competitors. For the Chemicals industry, the median ROE % is 5.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Specialties's current ROE % is 25.10%, which is 112% above median its own 10-year median of 11.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Specialties stock overvalued right now?
Based on GuruFocus' analysis, Resonance Specialties (BOM:524218) is currently considered Fairly Valued. The stock's GF Value™ is ₹140.91, compared to a current price of ₹149.15 — trading 5.8% above its estimated fair value. The current ROE % is 25.10%, which is 112% above median its 10-year median of 11.85 and 377.2% above the Chemicals industry median of 5.26. Resonance Specialties' overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Resonance Specialties (BOM:524218), the current ROE % is 25.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Resonance Specialties (BOM:524218) Overvalued in 2026?
Based on GuruFocus' analysis, Resonance Specialties stock appears to be overvalued.
The current stock price of ₹149.15 is trading 5.8% above its estimated GF Value™ of ₹140.91.
GuruFocus considers Resonance Specialties to be Fairly Valued.
Key valuation signals for BOM:524218:
ROE %: 25.10% (112% above median its 10-year median of 11.85)
GF Value™: ₹140.91 vs. price of ₹149.15 (5.8% above fair value)
Industry Position: 377.2% above the Chemicals median (#215 of 1583)
No single metric tells the full story. See the BOM:524218 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Resonance Specialties Ltd is engaged in the manufacturing of chemicals. The company is manufacturing Pyridine, Picoline, Cynopyridine, and derivatives of the same. Bulk drugs and nutritional products are tolls converted. It delivers pyridine and related products. The company has only one segment which is Chemical Manufacturing. The company also manufactures anti-tuberculosis products such as Isoniazid. Geographically. It operates in India and Outside India. The majority of segment revenue is from Outside India.
70GF Score
Get the complete analysis for BOM:524218
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524218 has been successfully added to your 
